Q&A with Chris­tine Baed­er, new chair of the gener­ic in­dus­try’s AAM

Gener­ic drugs are more of­ten than not the un­sung he­roes in health­care, gen­er­at­ing bil­lions in sav­ings every year and in­creas­ing ac­cess to vi­tal new med­i­cines as the brand-name ver­sions come off patent.

End­points News con­nect­ed with the new chair of the gener­ic in­dus­try’s As­so­ci­a­tion for Ac­ces­si­ble Med­i­cines, Chris­tine Baed­er, who is al­so Te­va’s COO, via video con­fer­ence on Fri­day.

Baed­er ex­plains be­low not on­ly what’s com­ing for AAM and its mem­ber gener­ic drug com­pa­nies, but al­so her thoughts on the In­fla­tion Re­duc­tion Act and the new five-year FDA user fee deal. Be­low is a light­ly edit­ed and con­densed ver­sion of the in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER